Lexeo Therapeutics
LXEO
59 hedge funds and large institutions have $426M invested in Lexeo Therapeutics in 2024 Q2 according to their latest regulatory filings, with 14 funds opening new positions, 27 increasing their positions, 13 reducing their positions, and 9 closing their positions.
108% more repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 13
56% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 9
18% more capital invested
Capital invested by funds: $362M → $426M (+$64.6M)
9% more funds holding
Funds holding: 54 → 59 (+5)
6.06% less ownership
Funds ownership: 86.69% → 80.63% (-6.1%)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
+$18.5M |
| 2 |
WP
Woodline Partners
San Francisco,
California
|
+$11.8M |
| 3 |
VPC
Vestal Point Capital
New York
|
+$9.66M |
| 4 |
Janus Henderson Group
London,
United Kingdom
|
+$9.05M |
| 5 |
Verition Fund Management
Greenwich,
Connecticut
|
+$5.24M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$8.08M |
| 2 |
AG
Artal Group
Luxembourg
|
-$2.88M |
| 3 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
-$2.73M |
| 4 |
CU
Cornell University
New York
|
-$1.98M |
| 5 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$1.75M |
LXEO Hedge Fund Activity: Q2 2024 in Review
59 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Lexeo Therapeutics (LXEO) for Q2 2024, worth a combined $426M — up 18% from $362M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new LXEO positions and 9 closed out — a net gain of 5 holders — while 27 added to existing stakes and 13 trimmed.
The largest buyer was Adage Capital Partners, adding an estimated $18.5M. The largest seller was Millennium Management, cutting an estimated $8.08M.
- 59 institutional investors held Lexeo Therapeutics (LXEO) as of Q2 2024, up from 54 in Q1 2024.
- Funds reported $426M of Lexeo Therapeutics stock for Q2 2024, up 18% quarter-over-quarter.
- 14 funds opened new Lexeo Therapeutics positions in Q2 2024 and 9 closed out, a net change of +5 holders.
- The largest Lexeo Therapeutics buyer in Q2 2024 was Adage Capital Partners, an estimated $18.5M added.
- The largest Lexeo Therapeutics seller in Q2 2024 was Millennium Management, an estimated $8.08M sold.
Based on aggregated 13F filings for Q2 2024.